Less than 10% of people who could benefit from GLP-1 drugs such as Wegovy can access them, states the WHO as it releases its initial guidance on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging increased and just availability to these injectable treatments.
According to estimates, more than two billion are projected to be obese by 2030 without intervention.
"Our new guidance acknowledges that excess weight is a lifelong illness that can be managed with comprehensive and lifelong treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are key hurdles to broad access to the treatments that can assist patients in reducing substantial body mass, notes the agency.
GLP-1 Therapy Supply Crisis
Even in the current best projected outlook, the manufacturing of these medications might only reach around 100 million people – less than 10% of those who need them, as stated by the health organization.
The recommendation urges governments and firms to widen access, through strategies such as licensing agreements.
The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in several nations in 2026.
How Obesity Jabs Function
The injections replicate a natural hormone to slow digestion, reduce hunger and enhance feelings of fullness so users consume fewer calories.
Individuals usually begin shedding pounds after several weeks of commencing the regular doses.
Studies indicates people may regain a significant portion after a year of discontinuing the drug, as their normal hunger come back.
To be above a healthy weight raises your likelihood for developing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight affects people in countries worldwide and was associated with millions of deaths worldwide in 2024, as per the health agency.
